Erythema nodosum-like lesions during BRAF inhibitor therapy: Report on 16 new cases and review of the literature

Journal of the European Academy of Dermatology and Venereology

Volumn 29, Issue 9, 2015, Pages 1797-1806

  Mossner R ^a   Zimmer, L ^b   Berking, C ^c   Hoeller, C ^d   Loquai, C ^e   Richtig, E ^f   Kahler K C ^g   Hassel, J C ^h   Gutzmer, R ⁱ   Ugurel, S ^j  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d Universitatsklinik fur Dermatologie   (Austria)

^e UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^f MEDICAL UNIVERSITY OF GRAZ   (Austria)

^g UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^h UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

ⁱ HANNOVER MEDICAL SCHOOL   (Germany)

^j UNIVERSITY OF WÜRZBURG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE INHIBITOR; DABRAFENIB; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; TRAMETINIB; VEMURAFENIB; B RAF KINASE; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; OXIME; SULFONAMIDE;

ADULT; AGED; ALGORITHM; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; ERYTHEMA NODOSUM; FEMALE; FEVER; HISTOPATHOLOGY; HUMAN; INFLAMMATION; LEG; MALE; MEDICAL RECORD REVIEW; MELANOMA; PANNICULITIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SKIN DEFECT; VASCULITIS; ANTAGONISTS AND INHIBITORS; BIOPSY; CASE REPORT; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; SKIN; YOUNG ADULT;

ADULT; AGED; BIOPSY; ERYTHEMA NODOSUM; FEMALE; HUMANS; IMIDAZOLES; INDOLES; MALE; MIDDLE AGED; OXIMES; PROTO-ONCOGENE PROTEINS B-RAF; RETROSPECTIVE STUDIES; SKIN; SULFONAMIDES; YOUNG ADULT;

EID: 84940439534     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.13039     Document Type: Article

References (24)

1. Sibaud V, Lamant L, Maisongrosse V, Delord JP,. [ Adverse skin reactions induced by BRAF inhibitors: a systematic review ]. Ann Dermatol Venereol 2013; 140: 510-520.
2. Chapman PB, Hauschild A, Robert C, et al,. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516.
3. Trinh VA, Davis JE, Anderson JE, Kim KB,. Dabrafenib therapy for advanced melanoma. Ann Pharmacother 2014; 48: 519-529.
4. Flaherty KT, Infante JR, Daud A, et al,. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367: 1694-1703.
5. Sinha R, Edmonds K, Newton-Bishop J, Gore M, Larkin J, Fearfield L,. Erythema nodosum-like panniculitis in patients with melanoma treated with vemurafenib. J Clin Oncol 2013; 31: e320-e321.
6. Novoa RA, Honda K, Koon HB, Gerstenblith MR,. Vasculitis and panniculitis associated with vemurafenib. J Am Acad Dermatol 2012; 67: e271-e272.
7. Villani AP, Zaharia D, Dalle S, Depaepe L, Balme B, Thomas L,. Vemurafenib-induced panniculitis. Eur J Dermatol 2013; 23: 258-260.
8. Monfort JB, Pages C, Schneider P, et al,. Vemurafenib-induced neutrophilic panniculitis. Melanoma Res 2012; 22: 399-401.
9. Zimmer L, Livingstone E, Hillen U, Domkes S, Becker A, Schadendorf D,. Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management. Arch Dermatol 2012; 148: 357-361.
10. Kim GH, Levy A, Compoginis G,. Neutrophilic panniculitis developing after treatment of metastatic melanoma with vemurafenib. J Cutan Pathol 2013; 40: 667-669.
11. Degen A, Volker B, Kapp A, Gutzmer R,. Erythema nodosum in a patient undergoing vemurafenib therapy for metastatic melanoma. Eur J Dermatol 2013; 23: 118.
12. Maldonado-Seral C, Berros-Fombella JP, Vivanco-Allende B, Coto-Segura P, Vazquez-Lopez F, Perez-Oliva N,. Vemurafenib-associated neutrophilic panniculitis: an emergent adverse effect of variable severity. Dermatol Online J 2013; 19: 16.
13. Chaminade A, Conte H, Jouary T, et al,. BRAF inhibitors-induced panniculitis: a cutaneous side effect mimicking subcutaneous melanoma metastasis. J Eur Acad Dermatol Venereol 2015; 29: 392-393.
14. West ES, Williams VL, Morelli JG,. Vemurafenib-Induced Neutrophilic Panniculitis in a Child with a Brainstem Glioma. Pediatr Dermatol 2015; 32: 153-154.
15. Cotton J, Armstrong DJ, Wedig R, Hood AF,. Melanoma-in-transit presenting as panniculitis. J Am Acad Dermatol 1998; 39 (5 Pt 2): 876-878.
16. Pierard GE,. Melanophagic dermatitis and panniculitis. A condition revealing an occult metastatic malignant melanoma. Am J Dermatopathol 1988; 10: 133-136.
17. Brazzelli V, Grasso V, Borroni G,. Imatinib, dasatinib and nilotinib: a review of adverse cutaneous reactions with emphasis on our clinical experience. J Eur Acad Dermatol Venereol 2013; 27: 1471-1480.
18. Assouline S, Laneuville P, Gambacorti-Passerini C,. Panniculitis during dasatinib therapy for imatinib-resistant chronic myelogenous leukemia. N Engl J Med 2006; 354: 2623-2624.
19. Prendiville J, Thiessen P, Mallory SB,. Neutrophilic dermatoses in two children with idiopathic neutropenia: association with granulocyte colony-stimulating factor (G-CSF) therapy. Pediatr Dermatol 2001; 18: 417-421.
20. Ball NJ, Cowan BJ, Hashimoto SA,. Lobular panniculitis at the site of subcutaneous interferon beta injections for the treatment of multiple sclerosis can histologically mimic pancreatic panniculitis. A study of 12 cases. J Cutan Pathol 2009; 36: 331-337.
21. Acland KM, Churchyard A, Fletcher CL, Turner K, Lees A, Dowd PM,. Panniculitis in association with apomorphine infusion. Br J Dermatol 1998; 138: 480-482.
22. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N,. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010; 464: 427-430.
23. Holderfield M, Nagel TE, Stuart DD,. Mechanism and consequences of RAF kinase activation by small-molecule inhibitors. Br J Cancer 2014; 111: 640-645.
24. Liu X, Ma B, Malik AB, et al,. Bidirectional regulation of neutrophil migration by mitogen-activated protein kinases. Nat Immunol 2012; 13: 457-464.